with the disease localized to the SB in one-third of patients with CD.

According to a study of Korean patients with CD, the SB was affected in approximately 90% of patients with CD. Localization of CD in the SB—and particularly if limited to this region—presents a diagnostic challenge, as conventional colonoscopy and small bowel follow-through (SBFT) are unable to directly visualize the SB. However, the introduction of SB diagnostic modalities such as capsule endoscopy (CE) and double-balloon enteroscopy have increased the rates of detection of SB CD.

SB assessment is currently considered a poor prognostic factor for long-term outcomes in CD.

CE can be utilized to assess various aspects of CD. It may provide confirmation of the diagnosis and assessment of the extent of disease in cases of suspected CD (sCD), while in established CD (eCD), it can be used to monitor disease activity, mucosal healing (MH), and postsurgical recurrence.

INTRODUCTION

Crohn’s disease (CD) is an IBD that can affect the entire gastrointestinal tract, the small bowel (SB) being the most commonly affected site. Previous studies on CD have shown SB involvement in approximately 70% of affected patients,

with the disease localized to the SB in one-third of patients with CD.

According to a study of Korean patients with CD, the SB was affected in approximately 90% of patients with CD. Localization of CD in the SB—and particularly if limited to this region—presents a diagnostic challenge, as conventional colonoscopy and small bowel follow-through (SBFT) are unable to directly visualize the SB. However, the introduction of SB diagnostic modalities such as capsule endoscopy (CE) and double-balloon enteroscopy have increased the rates of detection of SB CD.

CE can be utilized to assess various aspects of CD. It may provide confirmation of the diagnosis and assessment of the extent of disease in cases of suspected CD (sCD), while in established CD (eCD), it can be used to monitor disease activity, mucosal healing (MH), and postsurgical recurrence.
Establishing a diagnosis of SB CD is among the primary indications for CE. However, in eCD, CE is primarily used for monitoring CD activity, a key factor to determine the appropriate therapeutic strategy, especially owing to the recently changed focus of CD treatment from symptom control to reducing inflammation and achieving MH.

The diagnostic yield of CE for CD varies from 28% to 71%. A meta-analysis comparing the diagnostic yield of CE for CD against that of other imaging modalities showed that CE is superior to CT enterography (CTE). Although the role of CE in CD has expanded significantly, CE is not routinely used for the diagnosis and evaluation of CD in Korean patients. We aimed to investigate current practice patterns and evaluate the clinical significance of the use of CE in CD in Korean patients.

**METHODS**

1. **Study Design and Patients**

Between March 2003 and June 2015, 651 CE procedures were performed for various indications. Patients were excluded from the analysis if they had other SB diseases such as infectious disease, ischemia, vasculitis, tumor, or lymphoma. Finally, we retrospectively analyzed the medical records of patients who underwent CE in 57 cases of sCD and 14 cases of eCD. CE was not indicated for patients in whom obstructive symptoms or obstructive lesions were observed on radiological studies. Among all patients undergoing CE, 74.7% (53/71) underwent SBFT and/or abdominal CT for evaluating SB strictures. This study was approved by Soonchunhyang University Hospital Institutional Ethics Review Board (2015-07-025) and waived for informed consents.

2. **Definitions**

Criteria used to define sCD were the presence of at least 2 of the following: abdominal pain or diarrhea, iron deficiency anemia, elevated ESR or CRP levels, hypoalbuminemia, extraintestinal manifestations, and family history of IBD. eCD was defined as previously diagnosed cases of CD that fulfilled established diagnostic criteria (presence of symptoms and a combination of endoscopic, pathologic, radiologic, and/or laboratory abnormalities). Indications for CE were categorized as follows: (1) initial diagnosis, (2) differential diagnosis, (3) assessment of disease extent and activity, (4) assessment of MH, and (5) identification of postoperative recurrence. Performance of CE in patients with sCD who met the disease criteria was considered the “initial diagnosis” indication for CE. In cases in which evidence of CD, tuberculosis (TB), or other inflammatory diseases was observed in radiological findings obtained prior to CE, the performance of CE indicated “differential diagnosis of CD.” In the present study, the diagnostic criteria used to diagnose CD on the basis of the CE images obtained were the presence of >3 SB ulcerations (in the absence of history of NSAID ingestion) or >10 aphthous or erosive lesions showing either continuous or segment-like distribution. More frequently than CD, TB presents a patulous ileocecal valve, transverse ulcers, pseudopolyps, or cicatricial change. TB was considered in cases wherein CE revealed these findings. NSAID-induced enteropathy was diagnosed when CE revealed lesions such as reddened folds, denuded areas, red spots, mucosal breaks, or diarrheagmatic ulcers, with a history of NSAID ingestion. The phenotype was classified in accordance with the Montreal classification system. The final diagnosis was determined after integrating clinical manifestations, laboratory tests, and disease course based on CE findings. Conservative treatment included nil per os (NPO), total parenteral nutrition, transfusion, or iron replacement. Specific treatment included the addition or increased dosage of anti-inflammatory drugs, steroids, immunomodulators (IMs), or anti-TB medications.

3. **CE Procedure**

CE was performed using either the PillCam™ SB1/SB2 (Given Imaging, Yokneam, Israel) or the MiroCam™ (IntroMedic Co., Seoul, Korea). Prior to the procedure, patients underwent bowel preparation (using polyethylene glycol 1-2 L, Colyte™; Taejun Pharmacy, Seoul, Korea) and were kept NPO for at least 8 hours. Abdominal radiography was performed to confirm gastric retention of the capsule 2 hours after swallowing either the PillCam or the MiroCam. All images were reviewed by 2 board-certified endoscopists. The quality of CE images was classified as acceptable (excellent, good, or fair) or unacceptable (poor).

4. **Statistical Analysis**

Statistical analysis was performed using PASW Statistics version 18.0 for Windows (SPSS Inc., Chicago, IL, USA). The results are presented as means±SD or number (%). Continuous variables were analyzed using a two-tailed Student t-test or Fisher exact test. Categorical variables were analyzed using the chi-square test. A P-value of 0.05 was considered
RESULTS

1. Baseline Characteristics

The mean ages of the patients in the sCD and eCD groups were 45.8±15.9 and 37.4±17.0 years, respectively. Analysis of sex showed that 61.4% of patients in the sCD group and 78.6% of patients in the eCD group were male. In both groups, CE was performed in two-thirds of patients within 2 years of diagnosis of CD (sCD [85.9%] vs. eCD [64.2%]). A higher percentage of patients in the sCD group had a positive history of administration of NSAIDs, anticoagulants, or antiplatelet agents than in the eCD group (21.0% vs. 7.1%). At the time of CE, 71.4% of patients (10/14) in the eCD group were receiving treatment with only 5-aminosalicylic acid (5-ASA), and 28.6% (4/14) were receiving treatment with 5-ASA and steroids. A history of abdominal surgery was more common in the eCD group than in the sCD group (1.8% vs. 35.7%, \( P=0.001 \)). No significant differences were observed between the sCD and eCD groups with regard to the baseline laboratory characteristics listed in Table 1.

2. CE indication and CE-Related Data

In the sCD group, the most common indication for CE for CD was initial diagnosis (54.4%), followed by differential diagnosis (45.6%). Twenty-five of 57 patients with sCD (43.8%) presented with overt obscure gastrointestinal bleeding. Only 11.5% of patients in the eCD group (14/122) underwent CE. Although 3 of 14 patients with eCD received SB and/or colon resection prior to CE owing to CD, all CEs in patients with eCD were performed for the assessment of disease activity. No significant differences were observed in the percentage of patients in the sCD and eCD groups with regard to the type of CE, quality of images, arrival rate of capsule at the cecum, and SB transit time. Capsule retention was only observed in 1 patient (7.1%) in the eCD group. The capsule was removed endoscopically via double-balloon enteroscopy, and an IM was added to the patient’s treatment regimen. Table 2 displays the CE-related data.

Table 1. Baseline Characteristics of Patients with Suspected CD and Those with Established CD

| Characteristic                      | sCD                           | eCD                           | \( P \)-value |
|-------------------------------------|-------------------------------|-------------------------------|--------------|
| No. of patients                     | 57                            | 14                            |              |
| Age (yr)                            | 47 (16–75)                    | 29 (21–69)                    |              |
| Male sex                            | 35 (61.4)                     | 11 (78.6)                     | 0.351        |
| Disease duration <2 yr              | 49 (85.9)                     | 9 (64.2)                      | 1.000        |
| Medication use*                     | 12 (21.0)                     | 1 (7.1)                       | 0.439        |
| History of abdominal surgery        | 1 (1.8)                       | 5 (35.7)                      | 0.001        |
| Appendicitis                        | 0                             | 2                             |              |
| Small bowel resection               | 0                             | 1                             |              |
| Colon resection                     | 1                             | 1                             |              |
| Small bowel and colon resection     | 0                             | 1                             |              |
| Laboratory test                     |                               |                               |              |
| Leukocyte (/µL)                     | 5,950 (1,600–16,000)          | 6,800 (4,000–11,900)          | 0.533        |
| Hemoglobin (g/dL)                   | 10.3 (5.0–15.0)               | 10.6 (7.0–15.0)               | 0.557        |
| Platelet (10^3/µL)                  | 253 (105–463)                 | 279 (174–523)                 | 0.202        |
| ESR (mm/h)                          | 16.5 (11–116)                 | 13.5 (2–49)                   | 0.190        |
| CRP (mg/dL)                         | 0.17 (0.0–10.20)              | 0.13 (0.02–7.50)              | 0.847        |
| Albumin (g/dL)                      | 3.9 (2.1–5.2)                 | 4.1 (1.6–4.6)                 | 0.702        |
| Concordance rate between CE and SBFT| 7/19 (36.8)                   | 1/3 (33.3)                    | 0.197        |
| Concordance rate between CE and abdominal CT | 8/40 (20.0) | 1/6 (16.7) | 0.775        |

Values are presented as median (range) or number (%).

*Medication use means history of administration of NSAIDs, anticoagulants, or antiplatelet agents.
sCD, suspected CD; eCD, established CD; CE, capsule endoscopy; SBFT, small bowel follow-through.
Capsule endoscopy in CD

3. CE Findings and Final Diagnosis

In the sCD and eCD groups, the combined jejunal and ileal area represented the most common site of involvement (37.3% and 53.8%, respectively). Variable ulcerations were the most common findings in sCD (41.2%) and eCD (57.1%). Typical longitudinal ulcers were present in 23.5% and 14.3% of patients with sCD and eCD, respectively. The proportions of 14 patients with eCD with B1, B2, and B3 disease at diagnosis were 71.4%, 28.4%, and 7.1%, respectively. The proportions of patients with L1, L2, L3, L4, and L3+L4 disease were 28.6%, 28.6%, 14.3%, 7.1%, and 21.4%, respectively. Following CE, the location of CD was modified in 64.2% of patients (from L1 to L1+L4, n=4; from L2 to L2+L4, n=3; from L3 to L3+L4, n=2). The concordance rates between CE and SBFT/abdominal CT were 36.8%/20.0% and 33.3%/16.7% in the sCD and eCD groups, respectively; these findings were not significant. Table 3 summarizes the endoscopic findings including location of disease.

Of the 57 patients with sCD, 28.1% (16/57) were diagnosed with CD on the basis of CE findings; other diagnoses included tuberculous enteritis, NSAID-induced enteropathy, and other enteritis (Fig. 1), which were identified in 7.0%, 5.3%, and 17.5% of patients, respectively (Fig. 2). The overall diagnostic yield of CE was 59.7% (34/57).

4. Treatment and Adjustment of Therapeutic Strategies

The majority of patients in the sCD group (70.2%) were treated conservatively, while specific medications were initiated in 28.1% (n=14, 5-ASA; n=1, 5-ASA and steroid; n=1, anti-TB medication), and potentially disease-causing drugs (NSAIDs) were terminated for 1.8% of patients. In the eCD group, therapy was retained for 57.1% of patients (n=3, 5-ASA) or specific medication was added and/or increased (n=4, addition of steroid; n=1, dose increase of 5-ASA and addition of steroid), while 14.2% of patients were referred for surgery owing to obstructive symptoms following CE. Nevertheless, there were no dominant obstructive lesions on SBFT. The performance of surgery after CE was not associated with CE retention in any case. The final pathology revealed chronic transmural inflammation with granuloma, consistent with CD. Therapeutic strategies were changed for 70.2% of patients (40/57) in the sCD group and 50% of patients (7/14) in the eCD group on the basis of CE findings. Treatment results are summarized in Table 4.

DISCUSSION

We investigated practice patterns of CE use in Korea and the clinical impact of CE in patients with CD and arrived at...
3 main conclusions. First, in actual practice, we found that generally, CE was not performed for patients with eCD. Second, approximately one-fourth of patients with sCD were diagnosed with CD on the basis of CE findings. Third, therapeutic strategies were changed in >50% of patients with sCD or eCD based on the results of CE.

In Korea, the incidence and prevalence of CD are increasing rapidly. At the time of initial diagnosis, two-thirds of

Table 4. Treatment Modalities and Therapeutic Plan Adjustment for Patients with Suspected CD and Those with Established CD

|                | sCD (n=57) | eCD (n=14) |
|----------------|------------|------------|
| **Treatment modality** |            |            |
| Conservative treatment | 40 (70.2) | 1 (28.6) |
| Specific medication | 16 (28.1) | 8 (57.1) |
| **Therapeutic plan adjustment** | 40/57 (70.2) | 7/14 (50.0) |

Values are presented as number (%).

sCD, suspected CD; eCD, established CD.
CD cases involve the SB, and up to one-third of patients have lesions limited to the SB. As symptoms are usually nonspecific, the location of lesions in CD is very difficult to ascertain clinically. On diagnosing CD, it is important to ascertain the involvement of the SB and to evaluate and characterize any existing SB lesions. The main advantage of CE compared to other radiologic modalities such as SBFT, CT, and MRI is its ability to directly visualize the SB mucosa. Therefore, for patients with sCD, CE is used for diagnostic purposes because it distinguishes CD from other diseases such as intestinal TB and clearly delineates the extent and activity of disease.

In the present study, the most common indication for CE in patients with CD was to diagnose CD. In a meta-analysis comparing CE with SBFT, CTE, and MR enterography (MRE) in sCD, although there was no significant difference in diagnostic yield between CE and MRE (weighted incremental yield \(Y_I=7\%\), CE vs. MRE 50\% vs. 43\%), the weighted \(Y_I\) of CE was significantly superior to that of SBFT (weighted \(Y_I=32\%\), CE vs. SBFT 52\% vs. 16\%) and CTE (weighted \(Y_I=47\%\), 68\% vs. 21\%). The diagnostic yield of CE in patients with sCD ranges from 19\% to 77\%. In the current study, the overall diagnostic yield in the sCD group was 59.7\%, similar to that reported in a previous systematic review. CE alone was able to diagnose CD in more than one-fourth of the patients with sCD (28.1\%); most of the other patients in the sCD group had other causes of enteritis including TB. The potential usefulness of CE in patients with sCD should be emphasized, as the diagnosis of up to two-thirds of the patients in the sCD group was confirmed following CE, which enabled the institution of appropriate management.

In the present study, only ~10\% of the total group of patients with eCD underwent CE to assess disease extent and activity. In clinical practice, we can deduce that CE is not generally performed for the assessment of disease extent and activity, MH, or postoperative recurrence in patients with eCD. According to a previous study to assess MH using the Capsule Endoscopy Crohn's Disease Activity Index (CECDAI) in patients with SB CD beginning treatment with biologics or IMs, up to 30\% of patients showed MH at assessment 12 weeks after the initiation of treatment. In a recent study utilizing the Lewis score, only 15.4\% of patients in clinical remission had actually achieved MH on assessment by CE, while postoperative recurrence of CD was detected in up to 70\% of patients between 6 months to 1 year after ileocolonic resection. Severe endoscopic recurrence can be used as a surrogate marker of future clinical recurrence. Although MH is currently regarded as an important treatment strategy for patients with CD, data regarding the use of CE to evaluate MH as an indicator of treatment efficacy is limited to Western countries.

In the current study, we also found that CE was not performed for the assessment of MH or postoperative recurrence in patients with eCD, possibly owing to the risk of capsule retention, as it is relatively common for patients with eCD to have SB strictures, which are often considered a contraindication to CE. Therefore, the risk of capsule retention is one of the important factors limiting the use of CE in eCD. The risk of capsule retention was reported to be as high as 13\% in early studies; however, a pooled retention rate of 2.6\% was reported in a recent study. According to a recent guideline for CE in CD, SB radiological examination or patency capsule is recommended before CE for the evaluation of patients with eCD. However, not all patients with eCD could undergo SB radiologic examinations in the present study because some patients were enrolled at the time of their initial experience of CE in Korea. Nevertheless, we observed a lower percentage of capsule retention (1.4\%) compared to that in the aforementioned studies. The capsule was removed endoscopically, and the patient's treatment regimen was changed. These findings demonstrate that capsule retention does not always require surgical management, as the capsule can be removed endoscopically, and the disease can subsequently be managed using steroids, IM, or anti-tumor necrosis factor agents. Therefore, although capsule retention should be avoided, we believe that it may actually lead to appropriate treatment by allowing for localization of the culprit lesion.

CE can play an important role in aiding decision-making regarding therapy in patients with CD. According to a previous study, CE findings resulted in altered management plans for 90\% of patients with sCD and 73\% of patients with eCD. However, another study reported that a change in treatment was recommended in 52.3\% of patients on the basis of CE findings. In the present study, we found that therapeutic strategies for 70.2\% of patients in the sCD group were modified on the basis of CE findings; in the eCD group, 57.1\% of patients continued current medications or had a specific medication added. Overall, the results of CE resulted in alterations to the therapeutic plans of >50\% of patients in both the sCD and eCD groups.

The present study has several limitations. First, this study was a retrospective analysis and, as a single-center study, had a relatively small patient number. Second, a selection bias may have occurred because the assessment of patients with sCD and eCD was limited to those undergoing CE.
which could limit the strength of our conclusions. Third, although previous studies have described CE criteria for the diagnosis of CD (which we adapted for our study), diagnostic criteria for CE in patients with sCD remain unclear and subjective. It is difficult to distinguish TB or NSAID-induced enteropathy from CD because each of these can exhibit various inflammatory lesions and/or ulcers during CE. However, we attempted to perform the diagnoses as accurately as possible after integrating clinical manifestations, laboratory tests, and disease course based on CE findings. Prospective, multicenter studies are needed to more objectively determine CE-based diagnostic criteria for CD. Despite these limitations, we believe that the present study is valuable because it provides an analysis of the current practice patterns of CE use in Korea and highlights the scope of the expanded indications for the use of CE in the management of CD and the clinical significance of CE findings for patients with CD.

In conclusion, the most common indication for CE in CD was for the initial diagnosis, and CE was not generally performed in patients with eCD in clinical practice. CE appears to be an effective diagnostic modality for the evaluation of sCD, as well as a useful tool in the determination of therapeutic strategies for patients with sCD and those with eCD.

REFERENCES

1. Kornbluth A, Colombel JF, Leighton JA, Loftus E; ICCE. ICCE consensus for inflammatory bowel disease. Endoscopy 2005;37:1031-1054.
2. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001;49:777-782.
3. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140:1785-1794.
4. ASGE Technology Committee, Wang A, Banerjee S, et al. Wireless capsule endoscopy. Gastrointest Endosc 2013;78:805-815.
5. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis 2008;14:542-549.
6. Carter D, Eliakim R. Current role of endoscopy in inflammatory bowel disease diagnosis and management. Curr Opin Gastroenterol 2014;30:370-377.
7. Kopylov U, Nemeth A, Koulouzidis A, et al. Small bowel capsule endoscopy in the management of established Crohn’s disease: clinical impact, safety, and correlation with inflammatory biomarkers. Inflamm Bowel Dis 2015;21:93-100.
8. Lazarev M, Huang C, Bitton A, et al. Relationship between proximal Crohn’s disease location and disease behavior and surgery: a cross-sectional study of the IBD Genetics Consortium. Am J Gastroenterol 2013;108:106-112.
9. Kim M, Jang HJ. The role of small bowel endoscopy in small bowel Crohn’s disease: when and how? Intest Res 2016;14:211-217.
10. Kopylov U, Yablecovitch D, Lahat A, et al. Detection of small bowel mucosal healing and deep remission in patients with known small bowel Crohn’s disease using biomarkers, capsule endoscopy, and imaging. Am J Gastroenterol 2015;110:1316-1323.
11. Marmo R, Rotondano G, Piscopo R, et al. Capsule endoscopy versus enteroclysis in the detection of small-bowel involvement in Crohn’s disease: a prospective trial. Clin Gastroenterol Hepatol 2005;3:772-776.
12. Triester SL, Leighton JA, Leontiadis GI, et al. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with non-stricturing small bowel Crohn’s disease. Am J Gastroenterol 2006;101:954-964.
13. Solem CA, Loftus EV Jr, Fletcher JG, et al. Small-bowel imaging in Crohn’s disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc 2008;68:255-266.
14. Esaki M, Matsumoto T, Watanabe K, et al. Use of capsule endoscopy in patients with Crohn’s disease in Japan: a multicenter survey. J Gastroenterol Hepatol 2014;29:986-101.
15. Dionisio PM, Gurudu SR, Leighton JA, et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn’s disease: a meta-analysis. Am J Gastroenterol 2010;105:1240-1248.
16. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis 2010;4:7-27.
17. Yao T, Matsui T, Hiwatashi N. Crohn’s disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum 2000;43(10 Suppl):S85-S93.
18. Gay GJ, Delmotte JS. Enteroscopy in small intestinal inflammatory diseases. Gastrointest Endosc Clin N Am 1999;9:115-123.
19. Mehdizadeh S, Chen GC, Barkodar L, et al. Capsule endoscopy in patients with Crohn’s disease: diagnostic yield and safety. Gastrointest Endosc 2010;71:121-127.
20. Lee YJ, Yang SK, Byeon JS, et al. Analysis of colonoscopic findings in the differential diagnosis between intestinal tuberculosis and Crohn’s disease. Endoscopy 2006;38:592-597.
21. Gay G, Delvaux M, Frederic M. Capsule endoscopy in non-steroidal anti-inflammatory drugs-enteropathy and miscellaneous, rare intestinal diseases. World J Gastroenterol 2008;14:5237-5244.
22. Pons Beltrán V, González Suárez B, González Asanza C, et al. Evaluation of different bowel preparations for small bowel capsule endoscopy: a prospective, randomized, controlled study. Dig Dis Sci 2011;56:2900-2905.
23. Rameshshanker R, Arebi N. Endoscopy in inflammatory bowel disease when and why. World J Gastrointest Endosc 2012;4:201-211.
24. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res 2016;14:111-119.
25. Luján-Sanchis M, Sanchis-Artero L, Suárez-Callol P, Medina-Chuliá E. Indications of capsule endoscopy in Crohn’s disease. Rev Esp Enferm Dig 2014;106:37-44.
26. Hudesman D, Mazurek J, Swaminath A. Capsule endoscopy in Crohn's disease: are we seeing any better? World J Gastroenterol 2014;20:13044-13051.
27. Eliakim R, Suissa A, Yassin K, Katz D, Fischer D. Wireless capsule video endoscopy compared to barium follow-through and computerised tomography in patients with suspected Crohn’s disease: final report. Dig Liver Dis 2004;36:519-522.
28. Chong AK, Taylor A, Miller A, Hennessy O, Connell W, Desmond P. Capsule endoscopy vs. push enteroscopy and enteroclysis in suspected small-bowel Crohn's disease. Gastrointest Endosc 2005;61:255-261.
29. Efthymiou A, Viazis N, Vlachogiannakos J, et al. Wireless capsule endoscopy versus enteroclysis in the diagnosis of small-bowel Crohn's disease. Eur J Gastroenterol Hepatol 2009;21:866-871.
30. Liao Z, Gao R, Xu C, Li ZS. Indications and detection, completion, and retention rates of small-bowel capsule endoscopy: a systematic review. Gastrointest Endosc 2010;71:280-286.
31. Hall B, Holleran G, Chin JL, et al. A prospective 52 week mucosal healing assessment of small bowel Crohn’s disease as detected by capsule endoscopy. J Crohns Colitis 2014;8:1601-1609.
32. Pons Beltrán V, Nos P, Bastida G, et al. Evaluation of postsurgical recurrence in Crohn’s disease: a new indication for capsule endoscopy? Gastrointest Endosc 2007;66:533-540.
33. Vaughn BP, Moss AC. Prevention of post-operative recurrence of Crohn’s disease. World J Gastroenterol 2014;20:1147-1154.
34. Park SK, Ye BD, Kim KO, et al. Guidelines for video capsule endoscopy: emphasis on Crohn’s disease. Clin Endosc 2015;48:128-135.